Drug intelligence / Profile preview

QL-021

Development stage: Preclinical
Lead developer: Shenzhen Qinglan Biotechnology
Modality: Small Molecules
Administration: Transdermal

Overview

QL-021 is a small molecule drug candidate developed by BioQingLam for skin care applications. It utilizes a monomeric porphyrin-based active ingredient delivered via a proprietary soluble microneedle patch technology. This transdermal delivery system is designed to enhance the penetration and efficacy of the porphyrin molecule, which is often employed in dermatology for its photoactive or therapeutic properties. The drug is currently being evaluated in investigator-initiated trials (IIT) as part of BioQingLam's pipeline focusing on 505(b)(2) or hybrid innovation pathways.

Targets

Heme

Beyond the preview

Go deeper on QL-021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QL-021.

Explore the full profile